Published January 1, 2024
| Version v1
Journal article
Rethinking care management for older adults with cancer: Proposals from the "PRIORITES AGE CANCER" French group
Creators
- Galvin, Angéline
- Bertrand, Nicolas
- Boulahssass, Rabia
- de Decker, Laure
- Danquechin Dorval, Etienne
- Clairaz, Béatrice
- Castaignede, Monique
- Mourey, Loïc
- Baldini, Capucine
- Bauvin, Eric
- Jacques, Béatrice
- Mallon, Isabelle
- Durand-Zaleski, Isabelle
- Olivier, Guérin
- Krouri, Sadek
- Soubeyran, Pierre
- Bertrand, Nicolas
Contributors
Others:
- Bordeaux population health (BPH) ; Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS) ; Université de Lille-Centre Hospitalier Régional Universitaire [CHU Lille] (CHRU Lille)
- Pôle hospitalo-universitaire de gérontologie clinique [Nantes] ; Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)
- Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
- Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) ; Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Département d'Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP) ; Institut Gustave Roussy (IGR)
- Réseau régional de cancérologie Onco-Occitanie ; Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) ; Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Centre Émile Durkheim (CED) ; Sciences Po Bordeaux - Institut d'études politiques de Bordeaux (IEP Bordeaux)-Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)
- Centre Max Weber (CMW) ; École normale supérieure de Lyon (ENS de Lyon) ; Université de Lyon-Université de Lyon-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS)
- Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques (CRESS (U1153 / UMR_A 1125)) ; Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (INRAE)
- Institut de Recherche sur le Cancer et le Vieillissement (IRCAN) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UniCA)
Description
The growing incidence of cancer associated with an aging population implies major challenges for the care management of older adults with cancer. Several studies reported age as a limiting factor for access to cancer treatment, with older adults being less likely than younger patients to undergo surgery or receive anticancer drugs or radiation therapy. The main reason some treatments are not offered to older patients is to avoid overtreatment, i.e. to avoid either treatment of a cancer that would not have caused symptoms in the remaining lifetime, or treatment with serious adverse effects. These disparities are mainly based on higher risks of toxicity from anticancer drugs in older patients because of age-related comorbidities or vulnerabilities, which, when not based on objective evaluation, is a form of ageism. Indeed, being too cautious may lead to undertreatment with adverse consequences in terms of response to treatment or even survival. Poor representation of older patients in clinical trials is part of the explanation since high-quality evidence for treatment decisions is lacking. Older adults are often excluded from clinical trials, mainly on biological criteria or various tests rather than on valid criteria based on patient morbidities or vulnerabilities. Moreover, even when older patients are included, they are most often fit, and thus not representative of all older adults with cancer. Extrapolation of the results from studies on younger patients is not appropriate and more studies dedicated to older adults are therefore necessary, in particular with the aim of guiding therapeutic decisions.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.science/hal-04810516
- URN
- urn:oai:HAL:hal-04810516v1
Origin repository
- Origin repository
- UNICA